Chuck Silberstein, M.D., M.B.A., CFA
Chuck Silberstein, M.D., M.B.A., CFA, is a biotechnology executive with more than 25 years of experience across corporate finance, capital markets, business development and healthcare investing.
Most recently, he was Co-Founder and Chief Executive Officer of FytonBio. Previously, he served as Chief Financial Officer of GentiBio and as Chief Financial Officer and Head of Business Development at Applied Therapeutics, where he led activities across corporate finance, capital markets, investor relations, business development and strategic planning.
Earlier in his career, Dr. Silberstein served as Senior Vice President of Corporate Business Development and R&D Strategy at Allergan and held healthcare investment and research roles at J.P. Morgan Asset Management, The Boston Company Asset Management/BNY Mellon and Goldman Sachs Asset Management.
He holds an M.B.A. in Finance from Columbia Business School, an M.D. with Distinction in Research from Albert Einstein College of Medicine, and a B.A. in Biology from Yeshiva University. He is also a Chartered Financial Analyst and a licensed physician in New York State.